Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.
Q3 FY26 Earnings Results
- Revenue from Operations: ₹174.5 cr, +10.2% YoY vs ₹158.3 cr in Q3 FY25, steady growth in diagnostic services revenues.
- EBITDA: ₹47 cr, +24% YoY, EBITDA margin 30%, reflecting operational leverage from expanded network and efficiency gains.
- PAT: ₹19.4 cr, +50% YoY vs ₹12.97 cr in Q3 FY25, significant profit growth on higher scale and margins.
- EPS: ₹5.88 per share (normalized; up 48% YoY).
- Other key metrics: Total income (incl. other income) ₹296 cr reflecting service diversification and ancillary income.
Management Commentary & Strategic Decisions
- Management highlighted a healthy uptick in revenue and margins, attributing performance to increased patient volumes, expanded diagnostic footprints, and improved asset utilisation across pathology and radiology services. Commentary emphasised disciplined execution of PPP contracts and expansion in Tier-II/III markets.
- Leadership noted margin expansion driven by operating efficiencies and in-house service integration, underpinning sustainable profit growth. Strategic priorities remain on network expansion and service quality enhancement to capture growing demand for affordable diagnostics.
Q2 FY26 Earnings Results
- Revenue from Operations: ₹210.2 cr, +10.1% YoY (vs ₹190.9 cr in Q2 FY25).
- EBITDA: ₹59.2 cr, +19.9% YoY; EBITDA Margin 28.7%, stronger margins on operating scale.
- PAT: ₹23.95 cr, +22.2% YoY; PAT Margin 11.4%, good bottom-line expansion.
- EPS: ₹7.25 per share.
Management Commentary Q2
- In Q2, management cited solid revenue growth and margin improvement, with revenue and PAT up double-digits YoY, driven by expanding patient volumes and a broader service network.
- Commentary emphasised disciplined execution and operating leverage, supporting margin expansion even amid competitive pricing and cost headwinds.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.